AL-209 is a nine amino acid peptide currently in preclinical development. It has demonstrated potent neuroprotective effects in a number of neurodegenerative animal models such as Alzheimer’s disease, fetal alcohol syndrome and amylotrophic lateral sclerosis.

AL-309

AL-309 is a D-amino acid derivative of AL-209. It is in preclinical development for oral delivery and has demonstrated efficacy in animal models related to Alzheimer’s disease and fetal alcohol syndrome. Bioavailability studies show AL-309 is orally available, which has advantages in some circumstances compared to intravenous delivery routes for chronic daily dosing.

AL-408

AL-408 is a D-amino acid derivative of AL-108. It has demonstrated neuroprotective effects in animal models of Alzheimer's disease and fetal alcohol syndrome. The compound has also shown to be orally available, which makes it a suitable drug candidate for chronic neurodegenerative indications.